It's neo-adjuvant (treat prior to surgery) with a three mAbs: Ipi + Nivo, which is a well established combo of immunotherapeutics for many solid tumors, rounded out with relatlimab which I'm less familiar with (LAG-3 inhibition). Neoadjuvant use of immunotherapies is established concept and is utilized in clinical practice for non-small cell lung cancer and colon cancer. This is the first time I've seen a use of 3 immunotherapies used at once: Ipi + Nivo isn't the most tolerable treatment regimen. Other novel aspect is use of neoadjuvant therapy in GBM.
jsperx|1 year ago
trhway|1 year ago
mcbain|1 year ago
Once they primed his system they excised as much as possible and kept the immuno going while doing a course of radiation.
Profs Long and Scolyer work with melanoma where chemo is rarely used these days.
mft_|1 year ago
Yet there are settings where a deliberate combination of anti PD-1 with chemotherapy is the standard of care. And there are other types of immunotherapy where a combination with chemotherapy is advantageous too.
femto|1 year ago